ClinicalTrials.gg
CompletedNCT07628881Updated Oct 23, 2026

A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults

A Phase 1 interventional study of Sonrotoclax Tablet for Oral Suspension and Sonrotoclax Tablet in Healthy Volunteers, sponsored by BeOne Medicines. Completed at 1 site in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Other

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate whether blood levels of sonrotoclax after administration of a tablet for oral suspension are similar to those observed with the current sonrotoclax tablet. In addition, this study evaluates the effect of food on the absorption of sonrotoclax after administration of the tablet for oral suspension and the resulting blood levels of sonrotoclax.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BGB-11417
  • Sonrotoclax
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must sign the form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Participants who are overtly healthy as determined by no findings from medical history, clinical laboratory assessments, vital sign measurements, 12-lead (ECG), and physical examination at screening and check-in as determined by the Investigator, with additional requirements as follows:
  • (BMI) of 18.0 to 32.0 kg/m2 inclusive.
  • An absolute B-cell count of > 150 cells per microliter (cells/μL). If the B-cell count is \< 150 cells/μL, the assessment will be repeated. If the repeat value is > 150 cells/μL, the participant may be enrolled after consultation with the medical monitor.
  • Female participants of non- who meet any of the following criteria:
  • Surgically sterile (ie, through tubal ligation, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy).
  • , defined as: with no spontaneous menses for ≥ 12 months in the absence of prior chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle stimulating hormone (FSH) in the postmenopausal range.
  • Male participants are eligible if vasectomized or if they agree to the use of barrier with other highly effective methods if sexually active with women of childbearing potential, during study treatment and for at least 7 days after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Significant medical history or conditions: significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator or designee.
  • Investigator discretion: participants who, in the opinion of the Investigator or designee, should not participate in the study for any other reason.
  • or allergies: history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the Investigator or designee.
  • Stomach or intestinal surgery: history of gastrointestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
  • Surgery or trauma: major surgical procedure or significant traumatic injury within 3 months prior to check-in or anticipation of the need for major surgery during the study.
  • Medications affecting drug metabolism: use or intent to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St.John's wort, moderate/strong inhibitors or inducers, or P-glycoprotein (P-gp)/breast cancer resistance protein (BCRP) inhibitors, within 30 days prior to dosing
  • Infections: evidence of any infections (bacterial, viral, fungal, parasitic) within 4 weeks prior to the first dose of study treatment, as determined by the Investigator (or designee).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sonrotoclax Tablet for Oral Suspension

    Participants will receive each of the following treatments as a single dose on 3 separate occasions with an 8-day washout in between: 1. oral dose of sonrotoclax tablet for oral suspension administered in the fed state with a high-fat meal. 2. oral dose of sonrotoclax tablet for oral suspension administered after fasting 3. oral dose of sonrotoclax tablet administered in the fed state with a high-fat meal.

    Drug: Sonrotoclax Tablet for Oral Suspension · Drug: Sonrotoclax Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) for Sonrotoclax

    Time frame: Approximately 20 days

  2. Area under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) for Sonrotoclax

    Time frame: Approximately 20 days

  3. Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax

    Time frame: Approximately 20 days

Secondary outcomes

  1. Time of the Maximum Observed Concentration (Tmax) for Sonrotoclax

    Time frame: Approximately 20 days

  2. Apparent Terminal Elimination Half-life (t1/2) for Sonrotoclax

    Time frame: Approximately 20 days

  3. Apparent Total Clearance (CL/F) for Sonrotoclax

    Time frame: Approximately 20 days

  4. Apparent Volume of Distribution (Vz/F) for Sonrotoclax

    Time frame: Approximately 20 days

  5. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to approximately 47 days

  6. Number of Participants with Abnormal Clinically Significant Electrocardiogram (ECG) Values

    Clinically significant ECG values include a prolonged QT interval, presence of atrial fibrillation or other significant arrhythmia.

    Time frame: Up to approximately 47 days

  7. Number of Participants with Clinically Significant Vital Signs Measurements

    Vital signs include pulse rate, body temperature, and blood pressure.

    Time frame: Up to approximately 47 days

07

Study locations

1 site
  • Linear Early Phase
    Joondalup, Western Australia WA 6027, Australia
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Sep 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 5, 2026
StartActual
Jun 17, 2026
Primary completionActual
Sep 26, 2026
CompletionActual
Sep 26, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Primary completion
Sep 27, 2026→Sep 26, 2026 (actual)
Oct 23, 2026
Study completion
Sep 27, 2026→Sep 26, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Primary completion Sep 27, 2026→Sep 26, 2026 (now actual)
    Study completion Sep 27, 2026→Sep 26, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07628881
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Jun 17, 2026
Primary completion
Sep 26, 2026
Completion
Sep 26, 2026
Last update
Oct 23, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion